BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 17 2025
0mins
Source: SeekingAlpha
Delisting Notice: BrainStorm Cell Therapeutics received a Nasdaq delisting notice due to non-compliance with equity requirements, with trading suspended on July 18, 2025.
OTCQB Trading: The company has secured approval to trade on the OTCQB Venture Market under the same symbol "BCLI," starting on the same date as the Nasdaq suspension.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
